Improvements in the state of healthcare quality revealed
According to NCQA's annual State of Health Care Quality, improvements in measures related to high blood pressure and cholesterol control for people with diabetes were made compared with previous statistics. "High blood pressure is very common and, unfortunately, has been poorly controlled," says Earl Steinberg, MD, MPP, president and CEO of Resolution Health, a healthcare data analysis company that provides quality improvement and cost reduction services. "There is tremendous room for improvement on this measure. In addition, high blood pressure is something that the public understands. As a result, when public attention was focused upon this measure in 1999, health plans began efforts to improve blood pressure control-and those efforts are paying off."
NCQA's report shows that huge variations in quality remain commonplace. "Quality gap" is a term NCQA has coined to describe the gap in performance between the national average for a given performance measure and the rate achieved by the top 10% of health plans.
"For example, among the top 10% of health plans, about 68% of people who have had a heart attack have their cholesterol appropriately controlled," says Greg Pawlson, MD, NCQA's executive vice president. "But estimates of the national average for all persons say only about 50% [have it controlled]. So there's an 18 percentage point 'quality gap' between the two. It's important to track these gaps because they really represent the difference between what we could achieve if everyone were getting care in high-quality systems, and what we actually achieve. In this case we know that 68% is a reasonable target because many plans and practices already operate at that level. We also use these gaps to estimate how many lives might be saved if everyone received care through a top performing plan. The numbers are staggering: between 37,000 and 80,000 lives every year."
"Organizations that offer higher quality of care have a substantial advantage over their competitors and not just in terms of marketing and member loyalty. In the long run, it's better value for everyone to deliver high quality care, in terms of quality, cost and efficiency. You don't have to prevent a lot of second heart attacks or strokes to make controlling people's blood pressure and cholesterol a worthwhile investment," Dr. Pawlson says.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More